

1 **Multiplexed PCR to measure *in situ* growth rates of uropathogenic *E. coli* during**  
2 **experimental urinary tract infection.**

3 Santosh Paudel<sup>1</sup>, Geoffrey B. Severin<sup>1</sup>, Ali Pirani<sup>1</sup>, Evan S. Snitkin<sup>1,2</sup>, Harry L.T.  
4 Mobley<sup>1\*</sup>

5 <sup>1</sup>Department of Microbiology and Immunology, and

6 <sup>2</sup>Department of Internal Medicine, University of Michigan Medical School, Ann Arbor,  
7 USA

8

9 \*corresponding author

10 **Abstract**

11 Measuring bacterial growth rates *in vitro* is routine, however, determining growth rates  
12 during infection in host has been more challenging. Peak-to-trough ratio (PTR) is a  
13 technique for studying microbial growth dynamics, calculated using the ratio of  
14 replication origin (*ori*) copies to that of the terminus (*ter*), as originally defined by whole  
15 genome sequencing (WGS). WGS presents significant challenges in terms of expense  
16 and data analysis complexity due to the presence of host DNA in the samples. Here, we  
17 used multiplexed PCR with fluorescent probes to estimate bacterial growth rates based  
18 on the abundance of *ori*- and *ter*-adjacent loci, without the need for WGS. We establish  
19 the utility of this approach by comparing growth rates of the uropathogenic *Escherichia*  
20 *coli* (UPEC) strain HM86 by WGS (PTR) and qPCR to measure the equivalent *ori:ter*  
21 (O:T<sup>PCR</sup>). We found that PTR and O:T<sup>PCR</sup> were highly correlated and that O:T<sup>PCR</sup>  
22 reliably predicted growth rates calculated by conventional methods. O:T<sup>PCR</sup> was then  
23 used to calculate the *in situ* *E. coli* growth rates in urine, bladder, and kidneys collected  
24 over the course of a week from a murine model of urinary tract infection (UTI). These  
25 analyses revealed that growth rate of UPEC strains gradually increased during the early  
26 stages of infection (0–6h), followed by a slow decrease in growth rates during later time  
27 points (1-7 days). This rapid and convenient method provides valuable insights into  
28 bacterial growth dynamics during infection and can be applied to other bacterial species  
29 in both animal models and clinical infections.

30 **Importance**

31 Accurately measuring bacterial growth rates in the host, which plays a crucial role in  
32 determining the success of pathogens in establishing infections, poses significant  
33 challenges. To address this, bacterial replication rate has been measured as a proxy for  
34 growth rate estimation. While whole genome sequencing (WGS) has been used for this  
35 purpose, it comes with drawbacks such as high costs and difficulties in analyzing  
36 bacterial sequences due to the overwhelming presence of host DNA. In this study, we  
37 validate a more accessible PCR-based approach compared to the established WGS  
38 method and confirmed the reliability of our PCR-based technique. We then applied it to  
39 measure the growth rate of *Escherichia coli* during an experimental urinary tract  
40 infection in a mouse model. This study provides a cost-effective and efficient alternative

41 to WGS for studying bacterial replication dynamics during infection, potentially offering  
42 new insights into pathogen behavior and host-microbe interactions.

## 43 Introduction

44 Urinary tract infections (UTIs) are among the most prevalent bacterial infections, with  
45 *Escherichia coli* being the primary causative agent constituting approximately 75% of  
46 uncomplicated UTIs and 65% of complicated UTI cases (1). While the virulence factors  
47 and pathogenicity of uropathogenic *E. coli* (UPEC) (1–3), the *in vivo* growth dynamics  
48 during UTIs remain less understood. Bacterial replication rate is important to  
49 pathogenicity as it can influence evasion of the host response, colonization, and  
50 persistence (4). Understanding bacterial growth rates at different infection niches will  
51 also advance our knowledge of how each unique environment affects bacterial  
52 proliferation and the progression of infection and help pinpoint specific factors  
53 responsible for promoting or inhibiting bacterial growth.

54 Recent studies have established the use of bacterial circular chromosome replication as  
55 a means to determine growth rates with the underlying principle that rapidly growing  
56 bacteria have multiple replication forks starting at the origin (*ori*), leading to greater  
57 abundance of DNA proximal to the *ori* than distal sequences located near the terminus  
58 (*ter*) whereas slow growing or stationary phase bacteria have a more equitable number  
59 of *ori* and *ter* loci (Fig. 1). The ratio of sequencing coverage between the *ori* and *ter*,  
60 obtained from whole genome sequencing (WGS), is referred to as the peak-to-trough  
61 ratio (PTR) and was first applied by Korem *et al.* in 2015 for the determination of  
62 bacterial growth rates in a metagenomic study (5). Subsequently, a number of studies  
63 have utilized the concept of PTR to measure bacterial growth rates in a variety of  
64 conditions using WGS (5–12), digital droplet PCR (13), and SYBR green dye-based  
65 quantitative real time PCR (qPCR) (14). While WGS-based PTR has been widely  
66 applied and allows for the quantification of both *ori* and *ter* adjacent sequence  
67 abundance within the same sample, this method is expensive, requires computational  
68 resources and expertise, and generates an unnecessary amount of sequencing data if  
69 growth rate determinations are the sole objective. While techniques utilizing qPCR-  
70 based methods offer a more economical approach to specifically quantify *ori* and *ter*  
71 adjacent sequences, their reliance non-specific DNA-intercalating dyes necessitates the  
72 quantification of *ori* and *ter* abundance in the same sample be measured independently  
73 from one another. In our study, we combine both the ease of in-house qPCR with the  
74 WGS benefit of simultaneous measurement of *ori* and *ter* abundance in the same  
75 sample reaction by multiplexing qPCR reactions using TaqMan probes, we call O:T<sup>PCR</sup>.

76 The purpose of this study was two-fold: 1) To develop a probe-based multiplexed qPCR  
77 method for measuring *ori:ter* and 2) to use this method to determine the growth rates of  
78 UPEC strains *in vivo* during experimental urinary tract infection in mice. Validation of this  
79 approach streamlines the process of determining *ori:ter* to accurately and rapidly  
80 estimates doubling times in diverse biological samples. Measuring bacterial growth rate  
81 *in vivo* within host tissue may provide insight into the dynamics of experimental  
82 infections over time and the possibly clinical outcomes. After validating our qPCR  
83 method with conventional PTR measured by WGS, we determined the growth dynamics

84 of two UPEC strains HM56, and HM86 *in vivo* during experimental murine UTI for 7  
85 days post infection. We found both UPEC strains rapidly replicating in murine urine  
86 sample early in the infection (6–12 hpi) with grow rates slowly decreasing through the  
87 course of a week. This study demonstrates the usefulness of applying a probe-based  
88 qPCR method to measure UPEC growth rates in a clinically relevant model of UTI,  
89 which could be leveraged for use in various types of infections and models.

## 90 **Materials and methods**

### 91 **Bacterial strains and culture conditions**

92 *E. coli* strains HM56 and HM86 were isolated from cases of uncomplicated UTI and  
93 have been described elsewhere (15, 16). Bacterial strains were revived from the frozen  
94 stock (-80°C) by culturing overnight in Lysogeny broth (LB), aerating at 200 rpm at  
95 37°C. To conduct an *in vitro* experiment, the HM86 strain was cultured overnight with  
96 aeration at 37°C in LB, and inoculated 1:100 in fresh LB, terrific broth (TB), and M9  
97 minimal growth medium supplemented with 0.4% glucose (M9<sub>Glc</sub>). We sampled bacteria  
98 from the culture at 0, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6h to assess bacterial growth rate in  
99 different growth media, measuring absorbance (OD<sub>600</sub>) in cuvettes using GENESYS  
100 10S VIS spectrophotometer (Thermo Scientific). We collected bacterial pellets for each  
101 time point by centrifugation at 17K x g (Fisher Accuspin Micro 17R) for genomic DNA.  
102 The bacterial pellet was immediately placed in dry ice and stored at -80°C until further  
103 processing. Bacterial growth rate was determined using the formula:

104 Growth rate ( $GR_p$ ) =  $(\log(OD_{p+t}/OD_{p-t}))/dt$ , where “p” is the time point whose O:T<sup>PCR</sup>  
105 values is correlated with the growth rate, “p-t” is the initial OD, “p+t” is the final OD, “dt”  
106 is the time elapsed between initial and final OD. For our growth rate calculation, t=30  
107 minutes. Bacterial doubling time (DT) *in vitro* was calculated as  $[\log(2)/GR_p]$ .

### 108 **Quantitative polymerase chain reaction (qPCR)**

109 Genomic DNA (DNA) from *in vitro* bacterial culture samples and mice urine and organs  
110 were extracted using DNeasy® Blood and Tissue Kit (Qiagen, Germany) following  
111 manufacturer’s instruction. The qPCR was performed to determine the *ori:ter* ratio, a  
112 proxy of PTR (referred in this study as O:T<sup>PCR</sup>). The DNA concentration was estimated  
113 using Nanodrop One (Thermo scientific). The bacterial DNA in concentration of 500 pg  
114 was used to determine PTR for the *in vitro* samples. The targeted nucleotide sequences  
115 for the qPCR reaction near the origin of the replication (*ori*) is the *gidA* gene, and near  
116 the terminus of replication (*ter*) is the *dcp* gene.

117 The qPCR reaction was performed in QuantStudio 3 (Applied Biosystems) thermocycler  
118 (95°C 30 s, 40×(95 °C 5 s+58 °C 30 s). The optimized 25 µl reaction mixture contained  
119 12.5 µl TaqMan™ Fast Advanced Master Mix (Applied biosystems), 2.5 µl template  
120 DNA, and 10 µl of the reaction mixture of forward and reverse primer for *ori* and *ter*  
121 region (final primer concentration 1µM each), and probe for *ori* and *ter* sequence  
122 (concentration 0.25µM each). To ensure the reliability and accuracy of the qPCR results,

123 we repeated certain samples using a second set of primers that targeted the same  
124 region with the same probes for both set of primers. Primers (14, 17) and probes used  
125 for qPCR are provided in [Table 1](#). The  $O:T^{PCR}$  was determined using  $2^{-\Delta\Delta C_t}$  method  
126 ( $\Delta C_t = C_{t_{ori}} - C_{t_{ter}}$ ;  $\Delta\Delta C_t = \Delta C_{t_{test}} - \Delta C_{t_{reference}}$ ). The PTR for each sample is the average  
127 PTR of 3 technical replicates. The sample of the same bacterial strain cultured to  
128 stationary phase of growth, whose peak-to-trough is expected to be 1, is used for the  
129 normalization during each run. To evaluate the specificity of the primers and probes  
130 utilized in the experiment we performed two experiments: 1) using DNA from various  
131 Gram-positive and Gram-negative bacteria, both individually and mixed with *E. coli* DNA  
132 (1:1) to determine whether the presence of DNA from other bacterial sources affect the  
133 *ori:ter* ratio, and 2) inclusion of DNA extracted from murine kidney to assess the *E. coli*  
134 DNA-specificity of the qPCR in the presence of mouse genetic material. Molecular  
135 biology grade water (Corning) was used as non-template control (NTC) for each cycling  
136 run. The sample tested for PTR using WGS was incorporated in every set of the qPCR  
137 performed to minimize the experimental variability in PTR measurements between  
138 experiments. The qPCR assay was performed for the UPEC strains cultured *in vitro* in  
139 LB, TB, M9<sub>Glc</sub> and *in vivo* samples from the mouse during UTI.

#### 140 **Whole genome sequencing**

141 PTR values were determined using previously published methods (5, 6). Briefly,  
142 sequenced reads from each sample were cleaned and mapped to the complete genome  
143 sequence of the originating bacterial isolate using Trimmomatic v0.39 and Bowtie2  
144 v2.5.1. All alignments were indexed and sorted using SAMtools v1.18, and the coverage  
145 depth for each nucleotide position was extracted using Bedtools v2.30.0. A smoothing  
146 filter was applied to the mapped coverage of genomic segments, which was comprised  
147 of a moving sum with a window size of 10 kbp and a slide of 100 bp, followed by a  
148 moving median with a window size of 10-kbp bins and a slide of 100 bins. Instances  
149 where the bins did not have any mapped reads or had <50% remaining bins were  
150 discarded. The PTR was calculated from the peak and trough read coverage locations  
151 corresponding to maximum and minimum values, respectively, from the smoothed  
152 coverage (5). Snakemake implementation and analysis results can be accessed  
153 at [https://github.com/alipirani88/Growth-rate-estimate\\_SMAKE](https://github.com/alipirani88/Growth-rate-estimate_SMAKE). Assemblies for HM86  
154 and HM68 were generated with Flye 2.9.2 and annotated with Prokka 1.14.5. Origin and  
155 termination of replication sites were determined by blasting qPCR OriC and Ter loci  
156 using BLAST 2.14.0

#### 157 **Mouse model of ascending UTI**

158 Six-to-eight weeks old female CBAJ (Jackson laboratory) mice were inoculated  
159 transurethrally with  $\sim 2 \times 10^8$  CFUs of UPEC strains as described previously (18, 19).  
160 Briefly, the overnight culture of UPEC strains cultured with shaking at 37°C was  
161 centrifuged for 30 minutes at 3000 rpm and the bacterial pellet was resuspended in  
162 sterile PBS. Mice were anaesthetized using ketamine/xylazine intraperitoneally (IP).

163 Then, 50  $\mu$ l of bacterial suspension was inoculated transurethrally using a sterile  
164 polyethene catheter connected to an infusion pump (Harvard Apparatus). After the  
165 induction of the UTI, urine samples from the inoculated mice were collected at 6, 24, 48,  
166 72, 96, 120, 144, and 168 hpi for determination of CFUs and isolation of bacterial DNA.  
167 Mice were euthanized at 6, 24, and 168 hpi, and bladder and kidneys were collected for  
168 bacterial burden and bacterial DNA in the tissue samples. The bladder, and kidneys  
169 were collected in 5 ml culture tubes with 2 ml of ice-cold sterile PBS and homogenized  
170 using homogenizer (GLH 850, OMNI International). Bacterial burden from urine and  
171 each organ were enumerated using dilution plating by the drip-plate method and  
172 incubation at 37°C. The limit of detection (LOD) of bacteria in urine was 10<sup>3</sup> CFU/ml,  
173 whereas for bladder and kidney is 20 CFU/organ. Urine and tissue homogenates were  
174 centrifuged at 17K x g at 4°C for 5 minutes. The supernatant was discarded, and the  
175 pellet was placed immediately on dry ice and stored at -80°C until further processing for  
176 DNA to measure bacterial growth rate determining PTR.

## 177 **Statistical analysis**

178 Correlations between PTR and O:T<sup>PCR</sup>, and bacterial growth rate and O:T<sup>PCR</sup> were  
179 evaluated using Pearson's correlation coefficient. Linear regression analysis was  
180 performed to establish the relationship between growth rate and O:T<sup>PCR</sup>. Statistical  
181 significance of the doubling time (DT) measured by OD and PTR was determined using  
182 the paired *t*-test. Statistics and illustrations were performed using GraphPad Prism  
183 version 10 (GraphPad Software, CA, USA). A two-tailed *p*-value < .05 was considered  
184 statistically significant.

## 185 **Results**

### 186 **Validating multiplexed quantitative real time PCR with whole genome sequencing** 187 **as a tool for measuring origin to terminus ratios *in vitro***

188 To compare WGS PTR with our qPCR *ori:ter* method, we first generated a standard  
189 curve relating the growth rates of bacterial populations cultured *in vitro* to the relative  
190 abundance of the corresponding *ori* and *ter* sequences. This was achieved by culturing  
191 the *E. coli* strain HM86 in three different media where rapid and slow bacterial growth  
192 could be observed: lysogeny broth (LB), terrific broth (TB) and an M9 minimal medium  
193 containing glucose (M9<sub>Glc</sub>). Growth curves were initiated by addition of a one-to-one-  
194 hundred dilution of stationary phase HM86 culture into fresh medium and the optical  
195 density (OD<sub>600</sub>) of the bacterial population was measured at 30 to 60 minutes intervals  
196 over the six-hour period. Concurrent with these OD<sub>600</sub> measurements, cell pellets were  
197 collected for genomic DNA extraction from which the relative abundance of the *ori* and  
198 *ter* sequences in the bulk population were measured by both multiplexed qPCR and  
199 WGS.

200 As anticipated, *E. coli* HM86 grew rapidly in both rich media conditions (LB and TB)  
201 (Fig. 2 A) achieving exponential growth as early as 1.5 h post-inoculation and  
202 transitioning into stationary phase approximately two-hours later. In contrast, growth in

203 M9<sub>Glc</sub> was markedly slower with a longer lag phase and achieving a greatly reduced  
204 bacterial density over the course of six hours (Fig. 2A).

205 We first performed WGS on DNA samples collected throughout these growth curves to  
206 measure the relative abundance of *ori* and *ter* regions. Figure 2B illustrates one such  
207 read coverage plot from *E. coli* HM86 cultured in LB medium (Fig. 2A). During periods  
208 of rapid population expansion (1 – 3 h), we observed higher sequencing coverage (*i.e.*,  
209 peak) around the *ori* and lower sequencing coverage (*i.e.*, trough) corresponding with  
210 the location of the *ter*. As expansion of the population slowed, the relative abundance of  
211 reads mapping to the *ori* and *ter* regions normalized, resulting in a PTR of ~1. Plotting  
212 the PTR from WGS data across the rich media growth conditions (Fig. 2C) illustrates  
213 the dynamic transition in PTR throughout the course of the growth curves (LB and TB, n  
214 = 3) with mean maximal PTR being observed at 1.5 h (LB = 1.68 ± 0.14, TB = 1.73 ±  
215 0.1). While WGS was only performed for a single population of *E. coli* HM86 cultured in  
216 low nutrient M9<sub>Glc</sub>, the very modest changes in PTR predictably corresponded to the  
217 slow increase in culture density over time with a maximal PTR of 1.28 at 6 h (Fig. 2A).

218 We next tested whether multiplexing qPCR was a viable alternative to WGS for  
219 measuring the relative abundance of *ori* and *ter* sequences using these same *in vitro*  
220 DNA samples. Using previously published primers (14) and newly designed probes  
221 specific for regions near the *ori* and *ter*, we were able to rapidly generate *ori:ter* (O:T<sup>PCR</sup>  
222 ) for *E. coli* HM86 cultured in all three media (Fig. 2D). Similar to PTR (Fig. 2B), the  
223 relative *ori:ter* measured by O:T<sup>PCR</sup> in rich media were greatest during times of rapid  
224 population expansion with mean maximal *ori:ter* measured at 1.5 h (LB = 2.56 ± 0.12,  
225 TB = 2.69 ± 0.28) and this ratio gradually normalized to ~1 as cultures reached  
226 stationary phase (Fig. 2A). We also observed that the *ori:ter* in M9<sub>Glc</sub> also demonstrated  
227 a modest change in the O:T<sup>PCR</sup> reflective of the slow and limited expansion of the *in vitro*  
228 population over time (Fig. 2A) with a mean maximal *ori:ter* of 1.43 ± 0.05 measured at  
229 3.5 h. While the relationship between the *ori:ter* and *in vitro* culture growth phases were  
230 similar between PTR and O:T<sup>PCR</sup> in all three media, the maximal values of the *ori:ter*  
231 during times of population expansion were greater when measured by multiplexed  
232 qPCR than WGS (Figs. 2C & 2D). Despite differences in the absolute values of O:T<sup>PCR</sup>  
233 and PTR, we found the measurements *ori:ter* and PTR of each individual DNA sample  
234 were highly correlated in all three media conditions (Figs. 2E, 2F & 2G). The difference  
235 in absolute magnitude of *ori:ter* is likely reflective of a greater dynamic range in  
236 measuring *ori* and *ter* abundance by multiplexed qPCR and correlation of these  
237 measurements with PTR demonstrates the viability of using probe-based qPCR in lieu  
238 of WGS.

### 239 O:T<sup>PCR</sup> accurately predicts bacterial growth rate *in vitro*

240 Having demonstrated O:T<sup>PCR</sup> is a reliable method to measure *ori:ter*, we then calculated  
241 growth rates for each time point across every growth curve based on the OD<sub>600</sub>  
242 measurements that immediately preceded and followed that time point. A standard  
243 curve of growth rate and O:T<sup>PCR</sup> was then established from all time points where the

244 median growth rate from biological replicates cultured in same medium was less than  
245 0.0025 (*i.e.*, doubling time of 120 min) (Fig. 3A). This minimum doubling time criterion  
246 functionally incorporated all regions of the three growth curves where active growth  
247 could be observed (*i.e.*, excluded lag and stationary phases) and the  $O:T^{PCR}$  were in  
248 excess of 1.25 and these time points are illustrated as filled symbols in Fig. 1A and 1D.  
249 From these data, we could construct a standard curve and derive a linear equation  
250 ( $Y=0.007648*X-0.006786$ ) based on the relationship between growth rate and  $O:T^{PCR}$   
251 (Fig. 3A). We then used this equation to calculate a predicted growth rate for all  $O:T^{PCR}$   
252 measurements included in the standard curve and found no significant difference  
253 between the predicted growth rate and the experimentally derived growth from  $OD_{600}$   
254 measurements for each  $O:T^{PCR}$  measurement (Fig. 3B). The constraints of this standard  
255 curve are the maximum and minimum  $O:T^{PCR}$  measurements of 2.87 and 1.16  
256 representing a doubling times of 19.9 and 143.0 minutes, respectively. Therefore,  
257  $O:T^{PCR}$  which are greater or less than these extremes cannot be used to accurately  
258 determine bacterial growth rates and are instead defined as extremely rapid growth or  
259 slow growth, respectively.

## 260 **Establishing limits of *ori:ter* quantification, detection, and specificity of $O:T^{PCR}$**

261 Under optimal conditions, such as bacterial monoculture, bacterial DNA can be  
262 extracted, quantified, and used in downstream molecular applications with the  
263 knowledge that all the nucleic acids present originated from a single source. In an  
264 infection model, DNA extracted from a complex biological sample will be a mixture of  
265 both host and etiological agent derived nucleic acids. Additionally, the concentration of  
266 bacterial DNA within this sample will be unknown and likely to be in low abundance.  
267 Therefore, we established two constraints for accurate *ori:ter* determination by  $O:T^{PCR}$  in  
268 complex biological samples: a limit of quantification (LOQ) establishing the minimum  
269 number of CFU (LOQ-CFU) from which DNA could be extracted and accurately  
270 measured, and LOQ-DNA demonstrating the minimum quantity of bacterial DNA which  
271 can be accurately measured.

272 Because the total number of CFU collected in a biological sample from an infection model  
273 can vary, we chose to establish LOQ which would represent the minimum number of  
274 bacterial cells required to provide adequate template DNA for accurate  $O:T^{PCR}$   
275 determination. To establish this LOQ, we cultured *E. coli* HM86 to exponential phase in  
276 LB for 2 h from which 10-fold serial dilutions were prepared and DNA extractions of  $\sim 10^6$ ,  
277  $10^5$ ,  $10^4$ ,  $10^3$ ,  $10^2$ , 10, and 0 CFUs were performed. From these DNA extractions we found  
278 the relationship between *ori* and *ter* was measured to be approximately  $2.23 \pm 0.09$  by  
279  $O:T^{PCR}$  from templates originating from extractions containing  $10^6$  to  $10^3$  CFU, while those  
280 extracted from fewer CFU resulted in a significant deviation in this ratio (Fig. 4A).  
281 Therefore, an LOQ of  $\geq 10^3$  CFU is required to provide sufficient bacterial DNA template  
282 for accurate determination of *ori:ter* by  $O:T^{PCR}$ .

283 In a biological sample collected from the infection model, bulk DNA extraction is likely to  
284 capture DNA from both the infectious agent and the host. This complex mixture of nucleic



285 acids is likely to obscure the direct quantification of input template prior to its application  
286 in  $O:T^{PCR}$ . Because template abundance is correlated with critical threshold (Ct) values  
287 obtained by qPCR, we sought to define an LOQ based on the greatest Ct value for the  
288 *ori* specific oligo primers from which the relationship of *ori:ter* can be reliably determined  
289 by  $O:T^{PCR}$ . Using DNA extracted from  $\sim 10^8$  CFUs, described in LOQ experiment above,  
290 we performed  $O:T^{PCR}$  with 10-fold serial dilutions of template DNA (5 ng to 0.05 pg) to  
291 determine the range from which the *ori:ter* could be reliably measured.  $O:T^{PCR}$  containing  
292 5 ng to 0.5 pg template DNA consistently measured an *ori:ter* of approximately  $2.32 \pm 0.06$ ,  
293 and this ratio deviated as the template abundance fell below this range (Fig. 4B). Over  
294 the entire range of templates tested, the *ori* oligo Ct values reliably increased by a mean  
295 Ct of 3.41 per 10-fold dilution of template (ideal change is 3.32 Ct per 10-fold dilution).  
296 Based on these observations, we found the highest Ct value (*i.e.*, lowest template  
297 abundance) from which *ori:ter* could be determined by  $O:T^{PCR}$  was  $30.52 \pm 0.97$  cycles.  
298 This LOQ establishes a critical threshold for informing the appropriate conditions for the  
299 application of *ori:ter* measured by  $O:T^{PCR}$ ; where the *ori* oligo  $Ct \leq 30.52$ , the  
300 corresponding *ori:ter* can be confidently used to accurately calculate the growth rate of  
301 the bacteria in that sample.

302 As described above, biological samples collected from an infection model are likely to  
303 contain at least two sources of DNA; the infectious agent and the host. There also exists  
304 the possibility that samples can contain DNA extracted from other sources (*e.g.*, host  
305 commensals). To test the specificity of the *ori* and *ter* oligos to discriminate between *E.*  
306 *coli* and from other sources of DNA we performed  $O:T^{PCR}$  on mixed DNA templates  
307 containing 5 ng of *E. coli* HM86 DNA combined with 5 ng of DNA isolated from  
308 alternative sources. In the absence of extraneous DNA, the template composed of  
309 exclusively *E. coli* HM86 DNA had a  $16.04 \pm 0.13$  *ori* oligo Ct and a  $2.40 \pm 0.03$   $O:T^{PCR}$ .  
310 Addition of equal amount of DNA template purified from seven Gram-negative species  
311 cultured overnight (*Acinetobacter baumannii*, *Citrobacter freundii*, *Enterobacter*  
312 *hormaechei*, *Klebsiella pneumoniae*, *Morganella morganii*, *Pseudomonas aeruginosa*,  
313 *Serratia marcescens*), two Gram-positive species (*Bacillus subtilis* and *Staphylococcus*  
314 *aureus*) (Table 2), or host murine DNA (CBAJ) (Fig. 4B) did not significantly affect the  
315 detection of the *E. coli* HM86 template. While some reactivity with the *ori* and *ter* oligos  
316 was observed in the absence of *E. coli* HM86 DNA template for some of these alternative  
317 DNA samples, as well as the matrix control from the purification kit, the observed *ori* oligo  
318 Ct values were greater than the established LOQ above ( $\leq 30.5$  Ct) and would therefore  
319 be excluded from further analysis.

320 From these standardization and specificity experiments (Fig. 4), we found that *ori* and *ter*  
321 oligos are specific for *E. coli* HM86, extraction of  $> 10^3$  bacterial CFUs is needed to provide  
322 enough template for  $O:T^{PCR}$ , and a  $Ct \leq 30.5$  for the *ori* oligos is required to accurately  
323 quantify the *ori:ter* in a given sample. By applying these criteria as quality control  
324 measures for evaluating bacterial growth rates we can apply  $O:T^{PCR}$  to complex biological  
325 samples collected from an infection model.

326 To ensure the reliability of our PCR method in measuring *ori:ter* ratios, we validated the  
327 same primer oligos with the other *E. coli* strain, HM56. We cultured strain HM56 in LB  
328 medium for 6h and measured O:T<sup>PCR</sup> and found similar results to HM86, where HM56  
329 DNA behaves like HM86 DNA indicating that our qPCR method is robust and applicable  
330 across different *E. coli* strains (Fig. S1).

### 331 **Mouse model of ascending UTI**

332 Following parameterization of O:T<sup>PCR</sup>, we applied this method to measure *in vivo* bacterial  
333 growth rates in our model of interest, the experimental murine model of ascending UTI,  
334 over a period of seven days. For this, we induced experimental UTI in 6–7 week CBAJ  
335 female mice by transurethral catheterization and mono-culture inoculation of UPEC  
336 strains HM86 and HM56 isolated from uncomplicated female UTI patients (16, 20). Urine  
337 samples from the infected mice were collected at 6, 24, 48, 72, 96, 120, 144, and 168 hpi,  
338 whereas bladder and kidney samples were collected at 6, 24, and 168 hpi in a separate  
339 group of mice for bacterial burden and for extracting DNA and measuring growth rates  
340 from the two UPEC strains (Fig. 5).

341 Urine bacterial burden showed distinct patterns of colonization for each strain. *E. coli*  
342 HM56 urine samples exhibited higher initial counts at 6hpi, with high abundance of  
343 bacterial culture later up to 7 days period. In contrast, *E. coli* HM86 exhibited lower urine  
344 bacterial count at 6hpi, increased by 24hpi, and maintained a constant level of  
345 persistence throughout the infection period (Fig. 5B). Bladder colonization was similar  
346 for both strains, with higher level of colonization at 6hpi, which decreased by 24hpi, and  
347 remained at similar level up to 168hpi (Fig. 5C). The kidney colonization differed  
348 between the two strains. High level of kidney colonization was observed for *E. coli*  
349 HM56 at 6hpi, which was found to be lowered by approximately 10-fold at 168hpi.  
350 Conversely, *E. coli* HM86 exhibited limited kidney colonization early during the infection  
351 (6 hpi, 1 of 5 mice) which increased in abundance at later time points (24 hpi 2 of 5  
352 mice; 168 hpi 3 of 5 mice) (Fig 5D) indicating a slower time to ascension. These findings  
353 highlight strain-specific variations in colonization patterns during the progression of UTI,  
354 providing insights into the dynamics of bacterial colonization, dissemination, and  
355 persistence in the different sites of the urinary tract.

### 356 **Growth rate of UPEC strains *in vivo* during UTI**

357 Bacterial growth rates for HM86 and HM56 were next measured using DNA extracted  
358 from urine, bladder and kidney homogenates from infected animals. The recovery of  
359 bacterial DNA from the kidney sample was challenging due to the presence of host  
360 genetic material as evidenced by the observed Ct values compared to the recovered  
361 number of *E. coli* CFUs. However, the recovery was less affected in bladder and urine  
362 samples as observed Ct values were similar to the experiment performed with  
363 comparable known CFUs *in vitro* from pure bacterial culture. The DNA was extracted  
364 from urine, bladder, and kidney samples and *ori:ter* was determined. Fig. 6 illustrates  
365 the *ori:ter* values determined by qPCR from the urine samples during infection over the

366 period of 168h. We observed comparable patterns of *ori:ter* between the two tested  
367 strains over the infection timeline, which shows the variability in the replication rate.  
368 From this *ori:ter* -values we can predict that the growth rate of UPEC is higher at 6hpi,  
369 which gradually decreases over the infection period whose median *ori:ter* values is  
370 around our estimated borderline of the slow and fast growth conditions. No statistically  
371 significant difference was observed in *ori:ter* -values over the course of time.

372 The bacterial population doubling time was calculated from the qPCR derived *ori:ter*-  
373 values using the equation derived from the linear regression analysis of *E. coli* HM86 *in*  
374 *vitro* growth rate with their respective *ori:ter* value (Fig. 4D). The calculated *E. coli* DT in  
375 mouse urine is presented in Table 2. This DT results revealed a gradual increase in the  
376 growth rate of bacteria during the early stages of infection, peaking at 6h, followed by a  
377 slow decrease during later days transitioning to slower state of growth at 168hpi. The  
378 fastest median DT for *E. coli* HM56 and HM86 is 47.4 and 54.2 minutes, respectively,  
379 observed for both at 6 hpi. The fastest growth of *E. coli* HM56 was observed at 24 hpi  
380 with a DT of 28.9 minutes, while for *E. coli* HM86, it was found to be 31.3 minutes at  
381 6hpi. In case of individual mice, at 6hpi the fastest growth was determined as 31.6, and  
382 31.3 minutes for HM56, and HM86 respectively. During the later time points, the UPEC  
383 strains exhibited variable growth rates. This trend suggests that UPEC undergoes rapid  
384 multiplication in the urine during early stages of UTI, particularly within the first 6h,  
385 followed by a gradual slowdown in growth rate. The similarity in growth rate between the  
386 two strains implies a similar growth strategy among different UPEC isolates during  
387 infection. Due to the presence of lower number of CFUs in most of the bladder, we were  
388 only able to determine *ori:ter* in few bladder samples with Ct value within the range of  
389 LOQ. For HM86, the DT in bladder was found to be 33.3 minutes at 6hpi (1/5 mice),  
390 which was found slower at 24hpi with DT of 61.2 minutes (1/5 mice). No bladder had  
391 sufficient CFUs for *ori:ter* determination at 168hpi for HM86. For HM56, in contrast to  
392 HM86, we observed slower growth at 6hpi with DT of 63.1 and 71.2 minutes (2/5 mice),  
393 which became even slower at 24 and 168 hpi with DT of 76.8 (1/5 mice) and 81.2 (1/5  
394 mice) minutes respectively (Fig.S2-C). In contrast to the bladder, the growth rate in  
395 kidney was found to be slower at early stage of infection i.e. 6h followed by faster  
396 growth at 24 and 168 hpi for both *E. coli* strains. For HM56, the fastest growth rate was  
397 determined with DT of 76.6, 40.2, and 43.7 minutes at 6, 24, and 168 hpi, respectively.  
398 Since the kidney colonization with HM86 was limited, we were only able to determine  
399 the growth rate of 1 kidney samples at 6 and 168 hpi, with DT of 227.9 and 51.9  
400 minutes, respectively (Fig. S2-D). Overall, the results revealed the infection-site specific  
401 differences in the *E. coli* growth rate over the course of infection period.

## 402 Discussion

403 In this study, we developed a PCR-based method as a reliable alternative to WGS for  
404 determining bacterial growth rate targeting the specific regions near the origin and  
405 terminus of replication. As a proof-of-concept, the qPCR method was conducted on *in*  
406 *vitro* samples of *E. coli* HM86 cultured in both slow and rapid growth media and

407 validated the *ori:ter* with results obtained from the WGS method. The validation  
408 experiments were performed using the bacterial DNA isolated from the cultures grown  
409 under controlled laboratory conditions. This method provides an estimate of the  
410 population level PTR from the samples where the bacteria are at different stages in their  
411 growth cycle. A series of the control experiments were conducted to validate the growth  
412 rate measurements by *ori:ter* using qPCR method for bacterial replication rates in host  
413 tissues. We determined that  $>10^3$  bacterial CFUs in pure culture condition gives  
414 accurate *ori:ter* measurements with the Ct value of *ori* oligos around 30.5, equivalent to  
415 0.5 pg of the DNA used for *ori:ter* measurements. Therefore, we consider Ct values of  
416 30.5 or higher to be unreliable for determining *ori:ter*. This results ensures that the  
417 *ori:ter* measurements remains accurate even when dealing with low bacterial loads in  
418 host tissues during infection studies. Using this validated method, we measured the *E.*  
419 *coli ori:ter* during experimental UTI from urine, bladder, and kidney samples from mice.  
420 DNA extraction and *ori:ter* measurement in urine and bladder samples with the bacterial  
421 count above  $10^3$  CFUs resulted Ct value within the range of cut-off Ct value providing  
422 reliable result. This might vary as the recovery of DNA varies between the extraction  
423 protocol. Below this threshold, the consistency of the *ori:ter* was compromised,  
424 rendering inconsistencies of the result. In terms of DNA concentration, a total DNA  
425 amount of 0.5 pg was sufficient to produce a consistent *ori:ter* value, demonstrating the  
426 method's high sensitivity. We were only able to measure *ori:ter* from limited bladder  
427 samples since only a few bladder samples had sufficient bacterial counts to enable  
428 reliable *ori:ter* measurements within reliable range of Ct values. Although the colonized  
429 kidney samples had higher number of CFUs count than that required for accurate *ori:ter*  
430 measurement, we were not able to measure *ori:ter* from some kidney samples as the Ct  
431 values derived from the qPCR method were higher than the cut-off Ct values. This,  
432 however, was not due to the interference of the mouse kidney DNA to reading for  
433 bacterial DNA as evidenced by the experiment performed by adding 50 ng of the mouse  
434 kidney DNA to 0.5 pg of *E. coli* DNA without deviation in the Ct values and *ori:ter*  
435 measurements. This might be due to the inability of our DNA extraction protocol to  
436 recover enough bacterial DNA from the mouse kidney tissue homogenate.

437 Experiments using two sets of primers targeting the same region yielded similar results,  
438 confirming the reliability of the performed method. Since we employed a probe-based  
439 qPCR method, it was highly specific in amplifying the target sequence from the intended  
440 bacterial species. This approach allows us to amplify and measure two targeted  
441 chromosomal regions from a single sample using their specific probes, thereby reducing  
442 discrepancies in readings between wells for the replication origin and terminus regions  
443 when determining *ori:ter* measurements. This multiplexing capability is advantageous in  
444 reducing both costs and result discrepancies compared to running samples in separate  
445 wells for the two target regions.

446 From the *in vivo* growth rate experiment during UTI in mouse, we observed active  
447 growth in the urine samples with *ori:ter*  $>1$  in all samples. The fastest growth was  
448 observed during the early phase of infection for the tested UPEC strains which gradually

449 slowed during later days. Previously, the growth rate *in vivo* was determined in mouse  
450 UTI as well as human patients determining PTR, a sequencing-based method, which  
451 revealed that UPEC strains exhibit rapid growth during human UTIs, often matching or  
452 exceeding *in vitro* rates (6). Similar to this study, DT in mouse urine and bladder during  
453 experimental UTI at 6hpi was determined to be 34.9, and 36.9 minutes respectively,  
454 with much slower growth rate at 24hpi (6). To measure the growth rate *in vivo* during  
455 UTI, another study employed qPCR-based method targeting *ori* and *ter* region (21) from  
456 the urine sample of the infected human patients with UTI, where active growth with day-  
457 to-day and inter-patient variability in growth rate was observed (21). Notably, *E. coli*  
458 strains isolated from the urinary tract demonstrate significantly higher growth rates in  
459 urine compared to fecal isolates, suggesting adaptation to the urinary environment (6).  
460 The slow growth observed during the later stage of infection in the urine and bladder  
461 might be due to the multifaceted adaptive response to the challenging host environment  
462 such as activation of bacterial stress response mechanism, increased pressure from the  
463 host immune system, formation of protective biofilm, or the development of  
464 metabolically dormant persister cells. By slowing their growth, *E. coli* can manage  
465 nutrients to persist in nutrient-limited conditions, evade host immune responses, and  
466 maintain a viable population capable of resisting elimination and potentially causing  
467 recurrent infections. This strategy underscores the complex interplay between bacterial  
468 pathogens and host defenses in the context of chronic or recurring UTIs (22–28). In  
469 contrast to urine and bladder, the *E. coli* growth rate in the kidney was found to be  
470 higher during later stages of infection which highlights the niche-specific variations in  
471 growth pattern within different areas of the urinary system. The distinct growth dynamics  
472 in the kidney suggest that this organ provides a unique environment for *E. coli*  
473 proliferation as the infection progresses. From the bacterial burden and growth rate  
474 results, we did not observe the direct connection between growth rate and total number  
475 of CFUs recovered from urine, bladder, and kidneys.

476 The strategy of measuring *ori:ter* to study bacterial growth rate has been applied in  
477 other infection models, such as mouse peritonitis, revealing heterogeneous growth rates  
478 within bacterial populations during infection (14), and blood-stream infections (29)  
479 showing organ specific pattern of growth rate in multiple bacterial species. The method  
480 has also been tested with slower-growing pathogens like *Xylella fastidiosa*, showing  
481 promise for assessing growth status in plant and insect vector environments (30).  
482 Importantly, this approach has also been applied to predict antibiotic treatment efficacy  
483 (31).

484 In conclusion, our research establishes the effectiveness of a probe-based qPCR  
485 method for measuring *ori:ter* and *in situ* determinations of bacterial growth rate in a  
486 cost-effective and efficient manner. This approach of measuring bacterial growth rate by  
487 PCR has its potential application in various infection models across different bacterial  
488 species.

489

490 **Acknowledgements**

491 We would like to acknowledge the members of the Mobley lab and Bachman Lab for  
492 their insightful feedback throughout this project. This work was supported by the funding  
493 NIAID R01AI165582 (H.L.T.M.).

494

## 495 **References**

- 496 1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infections:  
497 epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol*  
498 13:269–284.
- 499 2. Klein RD, Hultgren SJ. 2020. Urinary tract infections: microbial pathogenesis, host–  
500 pathogen interactions and new treatment strategies. *Nat Rev Microbiol* 18:211–226.
- 501 3. Subashchandrabose S, Mobley HLT. 2015. Virulence and Fitness Determinants of  
502 Uropathogenic *Escherichia coli*. *Microbiol Spectr* 3:10.1128/microbiolspec.uti-0015–  
503 2012.
- 504 4. Smith H. 1990. Pathogenicity and the Microbe in vivo: The 1989 Fred Griffith Review  
505 Lecture. *Microbiology* 136:377–383.
- 506 5. Korem T, Zeevi D, Suez J, Weinberger A, Avnit-Sagi T, Pompan-Lotan M, Matot E,  
507 Jona G, Harmelin A, Cohen N, Sirota-Madi A, Thaiss CA, Pevsner-Fischer M, Sorek R,  
508 Xavier RJ, Elinav E, Segal E. 2015. Growth dynamics of gut microbiota in health and  
509 disease inferred from single metagenomic samples. *Science* 349:1101–1106.
- 510 6. Forsyth VS, Armbruster CE, Smith SN, Pirani A, Springman AC, Walters MS,  
511 Nielubowicz GR, Himpel SD, Snitkin ES, Mobley HLT. 2018. Rapid Growth of  
512 Uropathogenic *Escherichia coli* during Human Urinary Tract Infection. *mBio*  
513 9:10.1128/mbio.00186-18.
- 514 7. Szafrńska AK, Junker V, Steglich M, Nübel U. 2019. Rapid cell division of  
515 *Staphylococcus aureus* during colonization of the human nose. *BMC Genom* 20:229.
- 516 8. Gibson B, Wilson DJ, Feil E, Eyre-Walker A. 2018. The distribution of bacterial  
517 doubling times in the wild. *Proc R Soc B* 285:20180789.
- 518 9. Brown CT, Olm MR, Thomas BC, Banfield JF. 2016. Measurement of bacterial  
519 replication rates in microbial communities. *Nat Biotechnol* 34:1256–1263.
- 520 10. Long AM, Hou S, Ignacio-Espinoza JC, Fuhrman JA. 2020. Benchmarking microbial  
521 growth rate predictions from metagenomes. *ISME J* 15:183–195.
- 522 11. Joseph TA, Chlenski P, Litman A, Korem T, Pe'er I. 2022. Accurate and robust  
523 inference of microbial growth dynamics from metagenomic sequencing reveals  
524 personalized growth rates. *Genome Res* 32:558–568.
- 525 12. Emiola A, Oh J. 2018. High throughput in situ metagenomic measurement of  
526 bacterial replication at ultra-low sequencing coverage. *Nat Commun* 9:4956.

- 527 13. Schneiders S, Hechard T, Edgren T, Avican K, Fällman M, Fahlgren A, Wang H.  
528 2021. Spatiotemporal Variations in Growth Rate and Virulence Plasmid Copy Number  
529 during *Yersinia pseudotuberculosis* Infection. *Infect Immun* 89:10.1128/iai.00710-20.
- 530 14. Haugan MS, Charbon G, Frimodt-Møller N, Løbner-Olesen A. 2018. Chromosome  
531 replication as a measure of bacterial growth rate during *Escherichia coli* infection in the  
532 mouse peritonitis model. *Sci Rep* 8:14961.
- 533 15. Subashchandrabose S, Hazen TH, Brumbaugh AR, Himpsl SD, Smith SN, Ernst  
534 RD, Rasko DA, Mobley HLT. 2014. Host-specific induction of *Escherichia coli* fitness  
535 genes during human urinary tract infection. *Proc Natl Acad Sci* 111:18327–18332.
- 536 16. Sintsova A, Frick-Cheng AE, Smith S, Pirani A, Subashchandrabose S, Snitkin ES,  
537 Mobley H. 2019. Genetically diverse uropathogenic *Escherichia coli* adopt a common  
538 transcriptional program in patients with UTIs. *eLife* 8:e49748.
- 539 17. Riber L, Olsson JA, Jensen RB, Skovgaard O, Dasgupta S, Marinus MG, Løbner-  
540 Olesen A. 2006. Hda-mediated inactivation of the DnaA protein and dnaA gene  
541 autoregulation act in concert to ensure homeostatic maintenance of the *Escherichia coli*  
542 chromosome. *Genes Dev* 20:2121–2134.
- 543 18. Hagberg L, Hull R, Hull S, Falkow S, Freter R, Edén CS. 1983. Contribution of  
544 Adhesion to Bacterial Persistence in the Mouse Urinary Tract. *Infect Immun* 40:265–  
545 272.
- 546 19. Hagberg L, Engberg I, Freter R, Lam J, Olling S, Edén CS. 1983. Ascending,  
547 unobstructed urinary tract infection in mice caused by pyelonephritogenic *Escherichia*  
548 *coli* of human origin. *Infect Immun* 40:273–283.
- 549 20. Shea AE, Frick-Cheng AE, Smith SN, Mobley HLT. 2022. Phenotypic Assessment  
550 of Clinical *Escherichia coli* Isolates as an Indicator for Uropathogenic Potential.  
551 *mSystems* 7:e00827-22.
- 552 21. Haugan MS, Hertz FB, Charbon G, Sahin B, Løbner-Olesen A, Frimodt-Møller N.  
553 2019. Growth Rate of *Escherichia coli* During Human Urinary Tract Infection:  
554 Implications for Antibiotic Effect. *Antibiotics* 8:92.
- 555 22. Chromek M, Slamová Z, Bergman P, Kovács L, Podracká L, Ehrén I, Hökfelt T,  
556 Gudmundsson GH, Gallo RL, Agerberth B, Brauner A. 2006. The antimicrobial peptide  
557 cathelicidin protects the urinary tract against invasive bacterial infection. *Nat Med*  
558 12:636–641.
- 559 23. Nielsen KL, Dynesen P, Larsen P, Jakobsen L, Andersen PS, Frimodt-Møller N.  
560 2014. Role of Urinary Cathelicidin LL-37 and Human  $\beta$ -Defensin 1 in Uncomplicated  
561 *Escherichia coli* Urinary Tract Infections. *Infect Immun* 82:1572–1578.



- 562 24. Hayes BW, Abraham SN. 2016. Innate Immune Responses to Bladder Infection.  
563 *Microbiol Spectr* 4:10.1128/microbiolspec.uti-0024–2016.
- 564 25. Haraoka M, Hang L, Frendeus B, Godaly G, Burdick M, Strieter R, Svanborg C.  
565 1999. Neutrophil Recruitment and Resistance to Urinary Tract Infection. *J Infect Dis*  
566 180:1220–1229.
- 567 26. Haschka D, Hoffmann A, Weiss G. 2021. Iron in immune cell function and host  
568 defense. *Semin Cell Dev Biol* 115:27–36.
- 569 27. Ganz T, Nemeth E. 2015. Iron homeostasis in host defence and inflammation. *Nat*  
570 *Rev Immunol* 15:500–510.
- 571 28. Nairz M, Haschka D, Demetz E, Weiss G. 2014. Iron at the interface of immunity  
572 and infection. *Front Pharmacol* 5:152.
- 573 29. Anderson MT, Brown AN, Pirani A, Smith SN, Photenhauer AL, Sun Y, Snitkin ES,  
574 Bachman MA, Mobley HLT. 2021. Replication Dynamics for Six Gram-Negative  
575 Bacterial Species during Bloodstream Infection. *mBio* 12:10.1128/mbio.01114-21.
- 576 30. Sicard A, Castillo AI, Voeltz M, Chen H, Zeilinger AR, Fuente LDL, Almeida RPP.  
577 2020. Inference of Bacterial Pathogen Instantaneous Population Growth Dynamics. *Mol*  
578 *Plant-Microbe Interact* 33:402–411.
- 579 31. Haugan MS, Løbner-Olesen A, Frimodt-Møller N. 2018. Comparative Activity of  
580 Ceftriaxone, Ciprofloxacin, and Gentamicin as a Function of Bacterial Growth Rate  
581 Probed by *Escherichia coli* Chromosome Replication in the Mouse Peritonitis Model.  
582 *Antimicrob Agents Chemother* 63:10.1128/aac.02133-18.
- 583
- 584
- 585

586

## List of Tables

587 **Table 1. Primers and probes used in this study**

ID	Target sequence	Sequence	Reference
<i>oriC</i> F1	<i>gidA</i>	CGC AAC AGC ATG GCG ATA AC	PMID: <a href="#">30297723</a>
<i>oriC</i> R1	<i>gidA</i>	TTC GAT CAC CCC TGC GTA CA	PMID: <a href="#">30297723</a>
<i>ter</i> F1	<i>dcp</i>	TCA ACG TGC GAG CGA TGA AT	PMID: <a href="#">30297723</a>
<i>ter</i> R1	<i>dcp</i>	TTG AGC TGC GCT TCA TCG AG	PMID: <a href="#">30297723</a>
UPEC <i>oriC</i> Probe	<i>gidA</i>	/56-FAM/ACC CAT GAT /ZEN/GTG ATC CGC AGT AAC CTC GAT CGT A/3IABkFQ/	This study
UPEC <i>terC</i> Probe	<i>dcp</i>	/5SUN/CGC GCT AAA /ZEN/CCC GCC CTG CTG CTT AT/3IABkFQ/	This study
<i>oriC</i> F2	<i>gidA</i>	TCT CGT TTA TGG GCA ATG CG	This study
<i>oriC</i> R2	<i>gidA</i>	TGA TTT CTG TCG GCA AAG CG	This study
<i>ter</i> F2	<i>dcp</i>	GCG AGC GAT GAA TTA GCC TC	This study
<i>ter</i> R2	<i>dcp</i>	GCC TTC ATT CAA CAC CGT GT	This study

588

589

590 **Table 2. Specificity of *ori* and *ter* primers**

Template DNA source	O:T <sup>PCR</sup> (mean±SD)	Ct <sub>ori</sub> (mean±SD)	Ct <sub>ter</sub> (mean±SD)
<i>E. coli</i>	2.40±0.03	16.04±0.13	17.01±0.11
<i>E. coli</i> + <i>Citrobacter freundii</i>	2.44±0.07	16.08±0.12	17.07±0.08
<i>E. coli</i> + <i>Klebsiella pneumoniae</i>	2.61±0.16	15.94±0.09	17.03±0.04
<i>E. coli</i> + <i>Serratia marcescens</i>	2.57±0.04	16.00±0.03	17.08±0.01
<i>E. coli</i> + <i>Proteus mirabilis</i>	2.35±0.05	16.18±0.01	17.12±0.05
<i>E. coli</i> + <i>Acinetobacter baumannii</i>	2.57±0.02	15.89±0.16	16.96±0.14
<i>E. coli</i> + <i>Enterobacter hormaechei</i>	2.47±0.09	16.08±0.03	17.09±0.07
<i>E. coli</i> + <i>Morganella morganii</i>	2.46±0.03	16.01±0.07	17.02±0.06
<i>E. coli</i> + <i>Pseudomonas aeruginosa</i>	2.43±0.07	16.09±0.04	17.08±0.08
<i>E. coli</i> + <i>Bacillus subtilis</i>	2.41±0.03	16.09±0.12	17.07±0.14
<i>E. coli</i> + <i>Staphylococcus aureus</i>	2.46±0.19	15.93±0.18	16.93±0.08

591

592

593

594

595

596 **Table 3. *E. coli* doubling time in murine urine during experimental UTI**

	Doubling time (minutes) [Median (Min-Max)]	
Hours post-infection (hpi)	HM56	HM86
6	47.4 (31.6-105.2)	54.2 (31.3-90.5)
24	64.2 (28.9-153.1)	67.6 (38.3-142.5)
48	65.5 (36.8-70.9)	70.4 (46.9-89.1)
72	68.9 (59.8-148.0)	63.6 (42.0-99.7)
96	68.6 (55.3-128.1)	73.1 (64.5-76.8)
120	60.1 (46.4-70.1)	56.3 (40.8-80.5)
144	65.8 (58.5-68.4)	86.1 (52.8-104.1)
168	90.9 (63-129.1)	75.8 (46.5-139.2)

597

598

599

600

601

602

603

604

605


606

607

608

609


610 Figures



611

612


**Fig. 1. Determination of growth rate by PTR.** Stages of bacterial growth representing their *ori:ter* (one of the examples of *ori:ter* during exponential and stationary phase is shown. *ori*, green; *ter*, red).



613

614 **Fig. 2. Validating multiplexed quantitative PCR with whole genome sequencing as a tool**  
 615 **for measuring origin to terminus ratios in vitro.** Growth experiments of *E. coli* strain HM86  
 616 in different growth medium conditions are plotted as OD<sub>600</sub> reading (A) (mean ± SD). Means  
 617 and standard deviation from three independent experiments are shown for TB (red), LB (black),  
 618 and M9<sub>Glc</sub> (blue). Three biological replicates for TB, and LB, and two biological replicates for  
 619 M9<sub>Glc</sub>. (B) illustrates the example of the sequencing coverage across the genome of HM86  
 620 grown in vitro in LB up to 6h. Genomic location of origin (*ori*) and terminus (*ter*) of replication are  
 621 denoted by peak and trough respectively. PTR determined by WGS is plotted in (C) (mean ±  
 622 SD). (D) plots from the O:T<sup>PCR</sup> values (mean ± SD). Scatterplot with linear regression for the  
 623 relationship between PTR derived from WGS and *ori:ter* by qPCR method in TB (E), LB (F), and  
 624 M9<sub>Glc</sub> (G). N= 3 replicates (TB and LB), and N=1 (M9<sub>Glc</sub>). Pearson correlation coefficient (*r*) with  
 625 *p*-values are shown in the graph. Statistical significance. \*\*\*\*  $p < .0001$ ; \* $p < .05$ ). Filled symbols in  
 626 the graph A, C, and D indicates the data points with active replication included in the study for  
 627 growth rate determination.

628




629

630 **Fig. 3: Bacterial growth rate correlates with  $O:T^{\text{PCR}}$ .** Graph represents the correlation  
631 between GR and *ori:ter*-values determined by qPCR method in TBLBM9<sub>Glc</sub> (A). TB and  
632 LB=3 biological replicates, M9<sub>Glc</sub>= 2 biological replicates. Pearson correlation coefficient  
633 (*r*) with *p*-value is shown in the graph. Statistical significance: \*\*\*\*  $p < .0001$ ; \*\* $p < .01$ ).  
634 Bacterial growth rate calculated from the OD<sub>600</sub> reading and the qPCR<sub>*ori:ter*</sub> in  
635 TB+LB+M9<sub>Glc</sub> combined is plotted in Fig. B. Statistical significance was determined  
636 using the paired *t*-test, with  $p$ -value < 0.05 considered a significant difference.


637

638



639

640 **Fig. 4: PCR assay optimization.** Standard curves (Ct vs log<sub>10</sub>CFU) (A), and (Ct vs total  
641 DNA) (B) with their associated *ori:ter* determined by qPCR. Three replicates of the  
642 bacterial culture at exponential phase of growth (time point 2 h) was used for DNA  
643 extraction and determination of O:T<sup>PCR</sup> [CFU vs *ori:ter* experiment (mean ± SEM)], and  
644 3 independent experiment for total DNA vs *ori:ter* (mean ± SEM). The graph depicts *E.*  
645 *coli* strain HM86 *ori:ter*, Ct<sub>ori</sub>, and Ct<sub>ter</sub> in presence and absence of murine kidney DNA  
646 (data from 3 biological replicate with 3 technical replicates) as indicated in figure  
647 legends. EC (*E. coli* DNA) and mK (murine kidney DNA). DNA (data from 3 biological  
648 replicates with 3 technical replicates) as indicated in figure legends. Ct (threshold cycle),  
649 EC (*E. coli* DNA) and kidney (murine kidney DNA).




650

651 **Fig. 5: Bacterial burden in murine model of ascending UTI.** Experimental plan for  
652 mouse model of ascending UTI (A). CBAJ mice (n=5 per time point) were inoculated  
653 with either HM56 or HM86 with  $\sim 2 \times 10^8$  CFU. Viable bacterial load in urine (B), bladder  
654 (C) and kidneys (D) were determined by dilution plating in LB agar at specific time point  
655 as mentioned in the plot. The horizontal dashed line indicates the limit of detection



656 (LOD)



657

658 **Figure 6: O:T<sup>PCR</sup> in urine samples over infection period.** Box and whiskers plots,  
659 where box represents the median and interquartile ranges and whiskers represents  
660 minimum and maximum values for each time during infection for HM56 (A), and HM86  
661 (B). n= 5-15 mice per time point.

662

663

664

665

666

667

668

669

670

671

672

673

674


675

676

677


678

### Supplementary figures



679

680 **Fig. S1. O:T<sup>PCR</sup> of the UPEC strains HM86 and HM56 cultured in LB medium.** (n=3  
681 for HM86, and n=1 for HM56).



682

683 **Fig. S2. O:T<sup>PCR</sup> (Bladder-A, and Kidney-B) and *E. coli* doubling time (Bladder-C,**  
684 **and Kidney-D) of the mouse during experimental UTI at the time point of 6, 24,**  
685 **and 168 hpi.**